147 related articles for article (PubMed ID: 7694661)
1. Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia.
Aulitzky WE; Peschel C; Desprès D; Aman J; Trautman P; Tilg H; Rudolf G; Hüttmann H; Obermeier J; Herold M
Ann Hematol; 1993 Nov; 67(5):205-11. PubMed ID: 7694661
[TBL] [Abstract][Full Text] [Related]
2. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
3. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Geissler D; Gastl G; Aulitzky W; Tilg H; Gaggl S; Konwalinka G; Huber C
Leuk Res; 1990; 14(7):629-36. PubMed ID: 2388474
[TBL] [Abstract][Full Text] [Related]
6. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
7. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens.
Landmann R; Ludwig C; Wesp M; Fisscher A; Obrist R; Knüsli C; Denz H; Obrecht JP
J Interferon Res; 1992 Apr; 12(2):103-11. PubMed ID: 1374454
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.
Chiang J; Gloff CA; Yoshizawa CN; Williams GJ
Pharm Res; 1993 Apr; 10(4):567-72. PubMed ID: 8483840
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.
Liberati AM; Horisberger MA; Garofani P; De Angelis V; Ferrajoli A; Di Clemente F; Caricchi P; Adiuto D; Fedeli L; Palumbo B
J Interferon Res; 1994 Dec; 14(6):349-55. PubMed ID: 7897254
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo.
Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R
J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459
[TBL] [Abstract][Full Text] [Related]
11. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
12. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
Gilbert HS
Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
[TBL] [Abstract][Full Text] [Related]
13. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta.
Sperber SJ; Hayden FG
J Interferon Res; 1989 Jun; 9(3):285-93. PubMed ID: 2545792
[TBL] [Abstract][Full Text] [Related]
14. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b.
Fuchs D; Norkrans G; Wejstal R; Reibnegger G; Weiss G; Weiland O; Schvarcz R; Fryden A; Wachter H
Eur J Med; 1992; 1(4):196-200. PubMed ID: 1341444
[TBL] [Abstract][Full Text] [Related]
15. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint.
Dowding C; Guo AP; Maisin D; Gordon MY; Goldman JM
Br J Haematol; 1991 Feb; 77(2):165-71. PubMed ID: 2004017
[TBL] [Abstract][Full Text] [Related]
16. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype.
Krasagakis K; Garbe C; Krüger S; Orfanos CE
J Invest Dermatol; 1991 Aug; 97(2):364-72. PubMed ID: 1712824
[TBL] [Abstract][Full Text] [Related]
17. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
Aulitzky W; Gastl G; Aulitzky WE; Nachbaur K; Lanske B; Kemmler G; Flener R; Frick J; Huber C
Immunobiology; 1987 Dec; 176(1-2):85-95. PubMed ID: 3129362
[TBL] [Abstract][Full Text] [Related]
19. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
20. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]